What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Gene
His primary areas of study are Immunology, Internal medicine, Antiphospholipid syndrome, Antibody and Autoantibody.
His Immunology study frequently intersects with other fields, such as Odds ratio.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology and Surgery.
The study incorporates disciplines such as Lupus anticoagulant, Serology, Tertiary referral centre and Genotype in addition to Antiphospholipid syndrome.
Tatsuya Atsumi connects Lupus anticoagulant with International congress in his research.
Tatsuya Atsumi mostly deals with Beta 2-Glycoprotein I in his studies of Autoantibody.
His most cited work include:
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). (4564 citations)
- ANTIPHOSPHOLIPID ANTIBODIES AFFECT TROPHOBLAST GONADOTROPIN SECRETION AND INVASIVENESS BY BINDING DIRECTLY AND THROUGH ADHERED β2-GLYCOPROTEIN I (259 citations)
- Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. (252 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Immunology, Antiphospholipid syndrome, Antibody and Gastroenterology.
The various areas that Tatsuya Atsumi examines in his Internal medicine study include Diabetes mellitus, Endocrinology and Type 2 diabetes.
His works in Autoantibody, Autoimmune disease, Lupus erythematosus, Beta 2-Glycoprotein I and Immunopathology are all subjects of inquiry into Immunology.
He combines subjects such as Lupus anticoagulant, Anticardiolipin antibodies and Platelet with his study of Antiphospholipid syndrome.
His biological study spans a wide range of topics, including Molecular biology, Antigen and Clinical significance.
His Rheumatoid arthritis research integrates issues from Methotrexate, Surgery and Arthritis.
He most often published in these fields:
- Internal medicine (48.03%)
- Immunology (31.72%)
- Antiphospholipid syndrome (23.66%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (48.03%)
- Endocrinology (14.52%)
- Gastroenterology (14.52%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Endocrinology, Gastroenterology, Type 2 diabetes and Diabetes mellitus.
His study on Rheumatoid arthritis, Clinical trial, Glycemic and Insulin is often connected to In patient as part of broader study in Internal medicine.
Clinical trial is frequently linked to Antiphospholipid syndrome in his study.
His research on Antiphospholipid syndrome is centered around Antibody and Thrombosis.
The Gastroenterology study combines topics in areas such as Anti-neutrophil cytoplasmic antibody and Fatty liver.
His studies deal with areas such as Body mass index, Area under the curve and Confidence interval as well as Diabetes mellitus.
Between 2018 and 2021, his most popular works were:
- Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (40 citations)
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (33 citations)
- The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. (16 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Internal medicine, Antiphospholipid syndrome, Clinical trial, Antibody and Diabetes mellitus are his primary areas of study.
His work in the fields of Internal medicine, such as Rheumatoid arthritis, overlaps with other areas such as In patient.
Antiphospholipid syndrome is a primary field of his research addressed under Thrombosis.
His studies in Clinical trial integrate themes in fields like Adverse effect, Placebo, Tocilizumab and Oncology.
His study with Antibody involves better knowledge in Immunology.
His Immunology research incorporates elements of Extracellular and Necrotizing Vasculitis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
